Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.6680 EUR
−233.60 M EUR
159.67 M EUR
199.04 M
About Sangamo Therapeutics, Inc.
Sector
Industry
CEO
Alexander D. Macrae
Website
Headquarters
Richmond
Founded
1995
FIGI
BBG000BG48C6
Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which consist of inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on DUS exchange SANGAMO THERAP.INC.DL-,01 stocks are traded under the ticker GBY.
We've gathered analysts' opinions on SANGAMO THERAP.INC.DL-,01 future price: according to them, GBY price has a max estimate of 9.47 EUR and a min estimate of 1.89 EUR. Watch GBY chart and read a more detailed SANGAMO THERAP.INC.DL-,01 stock forecast: see what analysts think of SANGAMO THERAP.INC.DL-,01 and suggest that you do with its stocks.
Yes, you can track SANGAMO THERAP.INC.DL-,01 financials in yearly and quarterly reports right on TradingView.
SANGAMO THERAP.INC.DL-,01 is going to release the next earnings report on Feb 19, 2025. Keep track of upcoming events with our Earnings Calendar.
GBY earnings for the last quarter are 0.04 EUR per share, whereas the estimation was −0.01 EUR resulting in a 362.30% surprise. The estimated earnings for the next quarter are −0.09 EUR per share. See more details about SANGAMO THERAP.INC.DL-,01 earnings.
SANGAMO THERAP.INC.DL-,01 revenue for the last quarter amounts to 44.37 M EUR, despite the estimated figure of 18.79 M EUR. In the next quarter, revenue is expected to reach 9.80 M EUR.
GBY net income for the last quarter is 8.43 M EUR, while the quarter before that showed −33.73 M EUR of net income which accounts for 124.99% change. Track more SANGAMO THERAP.INC.DL-,01 financial stats to get the full picture.
No, GBY doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 16, 2024, the company has 405.00 employees. See our rating of the largest employees — is SANGAMO THERAP.INC.DL-,01 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SANGAMO THERAP.INC.DL-,01 EBITDA is −111.38 M EUR, and current EBITDA margin is −52.26%. See more stats in SANGAMO THERAP.INC.DL-,01 financial statements.
Like other stocks, GBY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SANGAMO THERAP.INC.DL-,01 stock right from TradingView charts — choose your broker and connect to your account.